PF-04691502是ATP竞争性PI3K(α/β/δ/γ)和mTOR抑制剂,Ki分别为1.8 nM/2.1 nM/1.6 nM/1.9 nM和16 nM,对Vps34,AKT,PDK1,p70S6K,MEK,ERK,p38和JNK几乎无活性。
PF-04691502 is a potent and selective, ATP-competitive PI3K/mTOR inhibitor with IC50 of 7.5 nM and 3.8 nM of AKT T308 and AKT S473, respectively. PF-04691502 is an ATP-competitive inhibitor which potently inhibits recombinant class I PI3K and FRAP and suppresses transformation of avian fibroblasts mediated by wild type PI3Kγ, δ or mutant PI3Kα. PF-04691502 has potential antineoplastic activity. PF-04691502 decreases phosphorylation of Akt T308 and Akt S473 in PIK3CA-mutant and PTEN-deleted cancer cell lines, and inhibits cell proliferation with (IC50 = 179 to 313 nM).
0-3 mM
每天 7.5 或 10 mg/kg 口服喂食
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Yuan et al (2011) PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol.Cancer Ther. 10 2189.
分子式 C22H27N5O4 |
分子量 425.48 |
CAS号 1013101-36-4 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 14 mg/mL |
Water <1 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT00927823 | Cancer | Drug: PF-04691502 | Pfizer | Phase 1 | 2009-12-01 | 2014-07-18 |
NCT01658176 | Breast Neoplasms | Drug: PF-04691502|Drug: Exemestane|Drug: Exemestane | Pfizer | Phase 2 | 2013-01-01 | 2012-10-26 |
NCT01430585 | Early Breast Cancer (Phase 2)|Advanced Breast Cancer (Phase 1b) | Drug: PF-04691502|Drug: PF-04691502 in combination with Letrozole|Drug: Letrozole | Pfizer | Phase 2 | 2012-03-01 | 2014-07-18 |
NCT01420081 | Endometrial Neoplasms | Drug: PF-05212384|Drug: PF-05212384|Drug: PF-05212384 | Pfizer | Phase 2 | 2012-01-01 | 2016-05-25 |
NCT01347866 | Advanced Cancer | Drug: PF-05212384|Drug: PD-0325901|Drug: PF-05212384|Drug: irinotecan | Pfizer | Phase 1 | 2011-10-01 | 2016-01-13 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们